1. Home
  2. IOT vs UTHR Comparison

IOT vs UTHR Comparison

Compare IOT & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Samsara Inc.

IOT

Samsara Inc.

HOLD

Current Price

$31.98

Market Cap

19.4B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$471.97

Market Cap

21.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOT
UTHR
Founded
2015
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.4B
21.4B
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
IOT
UTHR
Price
$31.98
$471.97
Analyst Decision
Buy
Buy
Analyst Count
12
12
Target Price
$50.42
$498.83
AVG Volume (30 Days)
5.8M
343.2K
Earning Date
03-05-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.08
EPS
N/A
26.38
Revenue
$1,520,629,000.00
$3,128,400,000.00
Revenue This Year
$29.12
$13.64
Revenue Next Year
$20.02
$5.66
P/E Ratio
N/A
$17.90
Revenue Growth
28.96
13.50
52 Week Low
$31.25
$266.98
52 Week High
$61.90
$519.99

Technical Indicators

Market Signals
Indicator
IOT
UTHR
Relative Strength Index (RSI) 33.83 40.80
Support Level $31.25 $455.63
Resistance Level $35.87 $473.89
Average True Range (ATR) 1.56 12.56
MACD -0.18 -3.43
Stochastic Oscillator 12.06 27.86

Price Performance

Historical Comparison
IOT
UTHR

About IOT Samsara Inc.

Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows.. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers ranges from small and medium-sized businesses to state and local governments.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: